Why Bristol-Myers Squibb (BMY) Is Buying Turning Point Therapeutics (TPTX) In A $4.1 Billion Deal

By Amit Chowdhry ● Jun 3, 2022
  • Bristol Myers Squibb (NYSE: BMY) is buying Turning Point Therapeutics, Inc. (NASDAQ: TPTX) in a $4.1 billion deal. These are the details.

Bristol Myers Squibb (NYSE: BMY) and Turning Point Therapeutics, Inc. (NASDAQ: TPTX) announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76 per share. The deal was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022.

Turning Point Therapeutics is known as a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis. And Turning Point Therapeutics’ lead asset, repotrectinib, is a next-generation, potential best-in-class tyrosine kinase inhibitor (TKI) targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer (NSCLC) and other advanced solid tumors. 

Repotrectinib was granted 3 Breakthrough Therapy Designations from the U.S. Food and Drug Administration. In the Phase 1/2 TRIDENT-1 clinical trial, a longer duration of response has been observed in the landmark analysis with repotrectinib than with existing ROS1 agents in first-line NSCLC.

Bristol Myers Squibb is expecting repotrectinib to be approved in the U.S. in the second half of 2023 and become a new standard of care for patients with ROS1-positive NSCLC in the first-line setting. And the company also plans to continue to explore the potential of Turning Point Therapeutics’ promising pipeline of novel compounds.

The deal supports Bristol Myers Squibb’s medium- to long-term growth strategy with accretion to non-GAAP earnings per share (EPS) beginning in 2025. And the deal is expected to be up to $0.08 per share dilutive to non-GAAP EPS in 2022 prior to any impact from an acquired in-process research and development charge based on the final accounting treatment. The accounting treatment as a business combination or asset acquisition will be determined upon the expected close of the transaction in the third quarter of 2022.

Under the terms of the merger agreement, Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of Turning Point Therapeutics’ common stock at a price of $76 per share in an all-cash transaction for a total consideration of $4.1 billion in equity value. And Turning Point Therapeutics’ Board of Directors unanimously recommends that Turning Point Therapeutics shareholders tender their shares in the tender offer.

The deal is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Turning Point Therapeutics’ common stock and the expiration or termination of the waiting period. Following the successful closing of the tender offer, Bristol Myers Squibb is going to acquire all remaining shares of Turning Point Therapeutics that are not tendered into the tender offer through a second-step merger at the same price of $76 per share.

Bristol Myers Squibb expects to finance the acquisition with cash on hand.

KEY QUOTES:

“The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset. With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile.”

— Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, Bristol Myers Squibb

“Today’s news builds upon our long legacy of pioneering next-generation medicines for patients with cancer. With repotrectinib, we have the opportunity to change the standard of care and address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients.”

— Samit Hirawat, M.D., Chief Medical Officer, Global Drug Development, Bristol Myers Squibb

“Through this transaction, we will be able to harness the full potential of our precision oncology platform to advance the standard of care for cancer patients. Since our founding, we have leveraged our deep scientific expertise to develop a pipeline of promising precision oncology assets. With Bristol Myers Squibb’s leadership in oncology, strong commercial capabilities and manufacturing footprint, we will be able to further accelerate the pace at which we can bring our novel medicines to benefit people diagnosed with cancer around the world.”

— Athena Countouriotis, M.D., President and Chief Executive Officer, Turning Point Therapeutics